Skip to main content
. 2021 Jun 4;11:649029. doi: 10.3389/fonc.2021.649029

Figure 5.

Figure 5

FHL3-mediated gastric cancer OHP resistance was verified in subcutaneous tumor model. (1) The tumors were harvested, and the tumor volume and weight in vivo were investigated (A, C and D), FHL3 knockdown could sensitize the efficacy of OHP treatment and inhibit tumor growth; (2) Tumor volume variation during 14 days of OHP treatment (B); (3) The ki-67 staining assay (100× magnification) was performed to show the cancer cell proliferation of every group (E).